Warner Pharmaceuticals announced that a total of 7 new varieties of the company have entered the national basic drug catalogue. Among them, four products, including colloidal pectin bismuth capsules), acetylcysteine solution for inhalation, ipratropium bromide solution for inhalation, and nifedipine sustained-release tablets, achieved total sales revenue of 132 million yuan in 2025, accounting for 8.78% of the company's revenue in 2025; the first quarter of 2026 achieved total sales revenue of 21.8037 million yuan, accounting for 6.72% of the company's revenue in the first quarter of 2026. There is no sales revenue for other products in 2025 or the first quarter of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.